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Introduction
Cocaine abuse remains a significant public health problem. The National Survey on Drug Use and Health estimated that, in 2013, 600,000 individuals tried cocaine for the first time, and 1.5 million Americans were considered regular users (Substance Abuse and Mental Health Administration, 2014) . Worldwide estimates put the number of regular cocaine users at nearly 20 million (United Nations Office on Drugs and Crime, 2014) . Despite longstanding efforts to develop pharmacotherapies (e.g., Dackis and O'Brien, 2003; Grabowski et al, 2004; Mello, 1990; Platt et al, 2002; Roberts and Brebner, 2000; Tanda et al, 2009; Vocci et al, 2005) , there are no approved medications for treating cocaine abuse.
Cocaine binds to dopamine, serotonin (5-HT), and norepinephrine transporters with similar affinity, although it is thought that abuse-related effects of cocaine are mediated predominantly by its capacity to increase dopamine neurotransmission (Ritz et al, 1987) . One approach for reducing these effects of cocaine is to target neurotransmitter systems and/or specific receptors that modulate (e.g., indirectly decrease or inhibit) dopamine neurotransmission. The ability of 5-HT systems to modulate dopamine activity is well documented, and mounting evidence suggests that these effects are mediated by the 5-HT 2 subfamily of receptors, with agonists acting at 5-HT 2A receptors stimulating dopamine release, and agonists acting at 5-HT 2C receptors inhibiting dopamine release within the nucleus accumbens. Conversely, antagonists of 5-HT 2A or 5-HT 2C receptors are known to decrease or increase dopamine neurotransmission, respectively (for review see Howell and Cunningham, 2015) .
Based on these effects, antagonists selective for 5-HT 2A receptors and agonists selective for 5-HT 2C receptors have been investigated for their ability to modify the behavioral effects of drugs of abuse, including cocaine. Although 5-HT 2A receptor antagonists (SR 46349B, M100907) inhibit the effectiveness of non-contingent cocaine injections to reinstate extinguished responding for cocaine (cocaine-primed reinstatement) at doses that do not alter the ongoing JPET #228833 self-administration of cocaine (Filip et al, 2005; Fletcher et al, 2002; Murnane et al, 2013) , 5-HT 2C receptor agonists (Ro 60-0175, WAY 163909) dose dependently inhibit the effectiveness of cocaine primes and cocaine-associated stimuli (cue-induced reinstatement) to reinstate extinguished responding, as well as the direct reinforcing effects of cocaine in selfadministration procedures (Burbassi and Cervo, 2008; Burmeister et al, 2004; Cunningham et al, 2011; Grottick et al, 2000; Manvich et al, 2012; Rüedi-Bettschen et al, 2015) . These findings suggest that 5-HT 2C receptor-selective agonists might be effective for reducing cocaine abuse and for prolonging abstinence.
Lorcaserin (Belviq ® ) is a selective 5-HT 2C receptor agonist (18-and 100-fold selective for 5-HT 2C over 5-HT 2A and 5-HT 2B receptors, respectively; Thomsen et al, 2008 ) that was approved in 2012 by the United States Food and Drug Administration (FDA) for the treatment of obesity.
In clinical studies, lorcaserin is well tolerated and decreases food intake and body weight (Aronne et al, 2014; Chan et al, 2013; Smith et al, 2009 Smith et al, , 2010 at doses that have low potential for producing heart valve disease (Weissman et al, 2013) or abuse (Shram et al, 2011) , effects commonly associated with 5-HT 2B and 5-HT 2A receptor agonists, respectively (Hutcheson et al, 2011; Nichols, 2004) . In addition to preclinical studies demonstrating that lorcaserin decreases food intake and body weight (Grottick et al, 2014; Higgins et al, 2013b; Smith et al, 2008; Thomsen et al, 2008) , lorcaserin also decreases nicotine self-administration and the reinstatement of responding for nicotine in rats (Higgins et al, 2012 (Higgins et al, , 2013b Levin et al, 2011) .
The current studies evaluated whether lorcaserin might have utility in treating cocaine abuse. Accordingly, the goals of these studies were to characterize the behavioral and pharmacokinetic profiles of lorcaserin and to assess its effectiveness to modify the discriminative stimulus and reinforcing effects of cocaine in rhesus monkeys. Because lorcaserin would be taken orally by cocaine abusers and because drug abuse is a chronic condition, the current studies characterized the effects of intra-gastric (i.g.) lorcaserin. In an attempt to broadly characterize the behavioral effects of lorcaserin, time course data were JPET #228833 6 collected for the effects of a range of doses of lorcaserin to alter locomotor activity and 24 distinct observable behaviors, as well as food-maintained responding. In order to assess its potential to alter abuse-related effects of cocaine, lorcaserin was also evaluated for its effectiveness to modify plasma concentrations of cocaine, antagonize the discriminative stimulus effects of cocaine, and reduce the self-administration of cocaine; the effects of lorcaserin on cocaine self-administration were assessed following both acute and repeated (14 days) administration. Together, these results provide preclinical evidence that lorcaserin attenuates some abuse-related effects of cocaine following acute and repeated administration and suggest that lorcaserin might be effective in treating cocaine abuse.
Methods
Subjects.
A total of 16 adult rhesus monkeys were used in these studies. One male (GO) and 3 female rhesus monkeys (PR, IR, LI), weighing between 6 and 9 kg, were used to characterize changes in locomotor activity and directly observable behaviors produced by lorcaserin. The male monkey (GO) and 2 of the female monkeys (PR, IR), along with one additional male monkey (CO; 9 kg), were used for the pharmacokinetic study. Three other male rhesus monkeys (HU, JO, LA), weighing between 8 and 11 kg, were used to investigate the effects of lorcaserin on food-maintained responding. A separate group of 3 male rhesus monkeys (MU, DU, LR), weighing between 8 and 11 kg, were used for the cocaine discrimination studies. Three male (BO, CH, PE) and 2 female rhesus monkeys (DA, RO), weighing between 6 and 10 kg, were used to evaluate the effectiveness of lorcaserin to inhibit cocaine self-administration. All monkeys were housed individually on a 14-h light and 10-h dark cycle with free access to water in their home cage. Surgical Preparation. Monkeys in the drug-discrimination and self-administration studies were surgically prepared with indwelling venous catheters connected to subcutaneous vascular access ports according to methods described elsewhere (Wojnicki et al, 1994 10, 15, 20, 30, 45, 60, 90 , and 120 min after cocaine administration. All blood samples were collected into 3 ml EDTA tubes (Vacutainer®, Bectin, Dickson and Company, Franklin Lakes, NJ) and immediately placed on ice and shielded from light. Within 30 min, the tubes were centrifuged at 1000 g for 10 min. Plasma was collected in polypropylene tubes containing 20 µl of a solution of 1 mg/ml sodium fluoride and 60% acetic acid and then stored at -80°C. Pharmacokinetic procedures were based on previous studies in which plasma cocaine levels were assessed in rhesus monkeys (Collins et al, 2012) .
Measurement of Lorcaserin and Cocaine in Monkey
Plasma. Milli-Q water was used for preparation of all solutions. Lorcaserin, cocaine, and deuterated cocaine (dCOC) super-stock solutions were prepared in methanol at a concentration of 1 mg/ml and stored in aliquots at -80° C. Working stock solutions (10 μ g/ml) of each analyte were prepared fresh each experimental day from the super-stock solutions and used to spike the calibrator samples.
The HPLC system consisted of a Shimadzu SCL-10A Controller, LC-10AD pump with a FCV-10AL mixing chamber, SIL-10AD autosampler, and an AB Sciex API 3200 tandem mass spectrometer with turbo ion spray. The analytical column was an Ace Excel 3 Super C18 (3 x 75 mm, 3 µ) purchased from MacMod (Chadds Ford, PA) and was maintained at 60° C during the JPET #228833 chromatographic runs in a Shimadzu CTO-10A column oven. Mobile phase A was 0.1% formic acid dissolved in Milli-Q water and mobile phase B was 0.1% formic acid dissolved in acetonitrile. The flow rate of the mobile phase was 0.6 ml/min. The gradient was as follows: 0 to 2 min, 10%B to 85%B linear; 2 to 3.4 min, 85%B; 3.4 to 3.5 min, 85%B to 10%B linear; 3.5 to 6 min, 10%B. The Q1/Q3 transitions used to quantify the analytes were 196.1→144.1 for lorcaserin, 304.1→182.2 for cocaine, and 307.2→185.3 for dCOC.
Sample Processing and Quantification of Lorcaserin and Cocaine in Plasma.
Lorcaserin and cocaine were quantified in monkey plasma. Briefly, 300 µl of calibrator and coded plasma samples were mixed with 50 µl of a 1 µg/ml dCOC solution (internal standard) and 2 ml of a mobile phase B (0.1% formic acid dissolved in acetonitrile). The samples were vortexed vigorously for 2 min and then centrifuged at 4925 g for 10 min at 23° C. Supernatants were dried to residue under a stream of nitrogen and then the residues were dissolved in 100 µl of 0.1% formic acid in water:acetonitrile (90:10). Then, 10 µl of the final samples were injected into the LC/MS/MS. The ratio of the peak area of each analyte to that of the internal standard dCOC (response ratio) for each unknown sample was compared against a linear regression of calibrator response ratios at spiked concentrations of 0, 1, 10, 100, 500, and 1000 ng/ml of lorcaserin and cocaine. Final concentrations of all analytes were expressed as ng/ml of plasma.
To test the effect of lorcaserin on the pharmacokinetic profile of cocaine, 4 monkeys received 1 mg/kg cocaine i.v. 90 min after i.g. administration of either saline or 3.2 mg/kg lorcaserin. Area under the curve (AUC) was calculated for the 2-h periods after administration of cocaine, and a two-tailed, paired t-test was performed to determine if lorcaserin altered the pharmacokinetic profile of cocaine. All statistical analyses were performed using GraphPad Prism 6 (La Jolla, CA, USA). cages where activity and directly observable signs were measured. Accelerometers were attached to collars and collected activity counts in 1-min bins continuously until they were removed from the collar. Directly observable behavior was measured 5, 15, 30, 60, 120, 240 min, and 24 hr after lorcaserin administration by 2 observers who were familiar with the behavior of these monkeys; 24 signs (Table 1) were recorded as present or absent during a 30-sec observation period at each time point. One observer administered drug and, therefore, was not blind to treatment; however, both observers were blind to the overall purpose of the experiment and expected outcomes. The level of agreement between the two raters of directly observable signs was determined using the κ statistic, which was calculated for signs that were increased by lorcaserin; reliability between observers was considered adequate for making definite conclusions when the value of κ exceeded 0.80 (Hallgren, 2012; Landis and Koch, 1977) .
Activity Monitoring and
Activity counts for the 5 minutes immediately following each observation period (e.g., consecutive responses on the infusion-appropriate lever (1 lever was designated correct for cycles preceded by administration of the training dose of cocaine, whereas the other lever was designated correct for cycles preceded by administration of saline) delivered a food pellet.
Response periods ended after delivery of 10 food pellets or 5 min, whichever occurred first; any remaining time before the next cycle was a timeout. During training sessions, cocaine could be administered prior to any of 6 cycles; however, that cycle was always the last cycle of the session. Saline was administered prior to any cycle that preceded administration of cocaine, or prior to all cycles if cocaine was not administered during that training session. Stimulus control was considered adequate for testing when the following criteria were satisfied for 5 consecutive or for 6 of 7 training sessions: at least 80% of the total responses for each cycle occurred on the infusion-appropriate lever and fewer than 10 responses (less than 1 FR) occurred on the incorrect lever before delivery of the first food pellet for each cycle. Thereafter, test sessions were conducted every third day as long as the testing criteria were satisfied during intervening training sessions; otherwise, training continued until the criteria were satisfied for 2 consecutive sessions.
Test sessions were identical to training sessions except that 10 consecutive responses on either lever delivered a food pellet. Either saline or lorcaserin (0.32-10 mg/kg; i.g.) was administered 75 min before 1 of 2 different types of test sessions. First, the time course for lorcaserin was determined by administering saline (i.v.) during each of 6 cycles, thereby examining the effects of lorcaserin 90-165 min after administration. Second, the ability of lorcaserin to alter the discriminative stimulus effects of cocaine was studied by obtaining cocaine dose-effect curves in a single session. During these sessions, saline was always administered during the first cycle, with increasing doses of cocaine administered during subsequent cycles. The first dose of cocaine was 0.032 mg/kg, which was administered during the second cycle and 90 min after administration of saline or lorcaserin. Thereafter, the cumulative dose of cocaine increased each cycle in ¼ log unit increments until at least 80% of responding occurred on the cocaine-appropriate lever or the rate of responding decreased to less than 20% of the control rate, whichever occurred first.
For individual monkeys discriminating cocaine, the percentage of total responses emitted on the drug lever during response periods was plotted as a function of dose. Control response rates are the mean of 10 training sessions during which only saline was administered and monkeys satisfied the testing criteria. For individual subjects, response rates were averaged first across cycles to obtain a mean for a session and then across sessions to obtain control rates. In subjects DU and LA, dose-response curves for cocaine administered alone or with lorcaserin were determined twice and are reported as the mean (± 1 SEM) whereas in subject MU each dose-response curve was determined once. Although the effects of each dose of lorcaserin alone were obtained 90-165 min after administration, the percentage of cocainelever responding obtained during the first cycle (response period occurred 85-90 min after lorcaserin administration) is shown. Discrimination data for an individual monkey were not included when response rates were less than 20% of control.
Cocaine Self-Administration. Five monkeys were trained to self-administer cocaine during daily 90-min sessions. Ninety minutes prior to each session, monkeys were briefly seated in chairs and given either saline or 1 of 4 doses of lorcaserin i.g. and returned to their home cage for the duration of the pretreatment period. During sessions, monkeys were placed in dark, ventilated, sound-attenuating chambers. One minute before the start of the session a loading infusion was administered to fill the catheter. The session began with a non-contingent priming infusion of 0.032 mg/kg cocaine which was delivered in conjunction with a 5-sec presentation of the cocaine-associated stimulus (i.e., a red light above the active lever). Immediately following the priming infusion, a green light was illuminated above the active lever signaling drug availability. Responding on the active lever (counterbalanced across monkeys) was reinforced by infusions of 0.032 mg/kg cocaine and a 5-sec presentation of the associated stimuli according to a FR30 schedule of reinforcement. Each contingent infusion was followed by a 180-sec timeout during which the chamber was dark and responses were recoded but had no scheduled consequence. Once the timeout period had elapsed, the green light was illuminated and cocaine was again available for responding under the FR30:timeout 180-sec schedule of reinforcement. Responding on the inactive lever was recorded but had no scheduled consequence. Saline was occasionally substituted for 0.032 mg/kg/infusion cocaine, in order to ensure that responding was being maintained by the cocaine infusions. was placed in the nostril and inserted until it reached the stomach at which point saline or lorcaserin was administered; the tube was then flushed with 10 ml of saline to insure the entire dose was administered. Figure 1 shows the pharmacokinetic profile of 3.2 mg/kg lorcaserin i.g. The concentration of lorcaserin in plasma reached a maximum of 80 ng/ml 60 min after administration. Plasma levels of lorcaserin were stable from 60 to 120 min. The pharmacokinetic profile of cocaine was evaluated twice in each monkey, once after saline and once after lorcaserin. The main panel in Figure 1 To assess whether the effects of lorcaserin in decreasing cocaine self-administration could be surmounted by larger unit doses of cocaine, on a separate occasion, monkeys were again treated with 3.2 mg/kg lorcaserin 90 min before daily sessions for 15 days. However, unlike the initial study that examined only 0.032 mg/kg/infusion cocaine, the unit dose of cocaine increased by ½ log unit every 5 sessions, from 0.032 to 0.1 to 0.32 mg/kg/infusion. When saline was administered 90 min before sessions, increasing the unit dose of cocaine produced a dosedependent decrease in the number of infusions and response rates (gray circles, Figure 7 ).
Results
Pharmacokinetics of Lorcaserin and Cocaine. The inset panel in
There was a main effect of lorcaserin on the number of cocaine infusions received, and this effect was dependent on the unit dose of cocaine ( 
Discussion
The results of the present studies demonstrate that lorcaserin decreases ongoing cocaine self-administration, that the effects of lorcaserin on cocaine self-administration are not surmountable when larger unit doses of cocaine are made available, that tolerance to lorcaserin does not develop over 14 days of once-daily treatment, and that attenuation of the effects of cocaine by lorcaserin is likely due to pharmacodynamic, and not pharmacokinetic, mechanisms.
Importantly, these effects of lorcaserin were observed at a dose that also produced yawning, a putative 5-HT 2C receptor-mediated effect, but smaller than doses that were required to produce large disruptions in food-maintained responding or spontaneous activity. Taken together, these findings in nonhuman primates suggest that lorcaserin, a drug with agonist activity at 5-HT 2C
receptors that was recently approved by the FDA for the treatment of obesity, might also be effective for treating cocaine abuse and addiction.
One goal of these studies was to characterize the behavioral effects of lorcaserin administered i.g., from ineffective doses to doses that significantly alter behavior. Lorcaserin was well tolerated up to a dose of 32 mg/kg and produced dose-and time-dependent effects on spontaneous activity, yawning, tongue movements, and food-maintained responding. Yawning began to emerge within 30 min of administration of 3.2 mg/kg, with yawning observed in all monkeys 60 and 120 min after drug administration. The time-course for yawning induced by 3.2 mg/kg lorcaserin closely matched plasma drug concentrations after administration of this dose, including the lack of behavioral effect and disappearance of lorcaserin in blood 24 hr after administration. These findings are consistent with a role for 5-HT 2C receptors in mediating the induction of yawning by drugs acting on 5-HT mechanisms (Collins and Eguibar, 2010; Pomerantz et al, 1993) . In addition to yawning, larger doses of lorcaserin also decreased spontaneous activity and food-maintained responding in all monkeys and produced oral-facial stereotypies (i.e., abnormal tongue movements) in a subset of monkeys. Taken together, these findings suggest that i.g. administration of 3.2 mg/kg lorcaserin results in plasma drug concentrations that are sufficient to produce putative 5-HT 2C receptor-mediated effects without markedly disrupting spontaneous or operant behavior.
Based on the behavioral and pharmacokinetic profiles of lorcaserin, a 90-min pretreatment time was used to evaluate the effectiveness of lorcaserin to alter behavioral effects of cocaine that are related to its abuse, including discriminative stimulus effects and reinforcing effects. When administered alone, over a wide range of doses lorcaserin failed to substantially increase responding on the cocaine-associated lever. Although these are the first studies to evaluate lorcaserin in animals trained to discriminate cocaine, they are in agreement with previous studies in rats discriminating MK 212, a less selective 5-HT 3/2C/2B receptor agonist (Callahan and Cunningham, 1995) and suggest that 5-HT 2C receptor agonists, such as lorcaserin, do not share discriminative stimulus effects with cocaine. When administered before cocaine, 1 mg/kg lorcaserin shifted the cocaine dose-response curve downward or rightward in 2 of 3 monkeys. Although modest, these shifts in dose-response functions are similar in magnitude to results reported for combinations of MK 212 and cocaine in rats and suggest that lorcaserin does not enhance, but rather attenuates, the discriminative stimulus effects of cocaine after i.g. administration. Although these studies were not designed to elucidate the mechanism(s) by which lorcaserin inhibits the effects of cocaine, given that lorcaserin did not alter the pharmacokinetic properties of cocaine, it is likely that these effects are mediated by its actions at 5-HT 2C receptors. Consistent with this notion is the finding that 5-HT 2C receptor
antagonists (e.g., SDZ SER-082) can enhance the discriminative stimulus effects of cocaine (Filip et al, 2006) and that 5-HT 2C receptor agonists and antagonists appear to modify the effects of cocaine by inhibiting and enhancing dopamine transmission, respectively (for reviews see Cunningham, 2006, 2008) .
Unlike typical pharmacotherapies for drug abuse, which often target the primary site of action of the abused drug (e.g., methadone and naltrexone, both acting at mu opioid receptors, for treating opioid addiction), it is also possible to reduce abuse-related effects through actions at sites other than the primary site of action of the abused drug. Because of their role in modulating dopamine neurotransmission, 5-HT 2C receptors have received considerable attention as a potential target for treating cocaine abuse (Higgins and Fletcher, 2015; Higgins et al, 2013a; Howell and Cunningham, 2015) ; however, the relative lack of highly selective compounds has limited a full characterization of the effectiveness of 5-HT 2C receptor agonists to reduce cocaine self-administration. Lorcaserin is 18-and 100-fold selective for 5-HT 2C over 5-HT 2A and 5-HT 2B receptors, respectively . In the present studies, lorcaserin, dose dependently decreased rates of responding and number of cocaine infusions received, with significant decreases observed for both measures following i.g. administration of 3.2 mg/kg lorcaserin. It is unlikely that this suppression of cocaine self-administration reflects a leftward shift in the cocaine dose-response curve insofar as lorcaserin shifts the cocaine selfadministration dose-response curve to the right in monkeys responding under a progressive ratio schedule (unpublished observation). Taken together, these findings are consistent with the acute effects of the 5-HT 2C receptor agonists WAY 163909 and Ro 60-0175 in rats and squirrel monkeys, respectively (Cunningham et al, 2011; Manvich et al, 2012; Rüedi-Bettschen et al., 2015) , and provide further support for the notion that targeting 5-HT 2C receptors could provide an effective strategy for treating cocaine addiction.
In addition to assessing the acute effects of lorcaserin, the current studies also evaluated the effectiveness of lorcaserin across 14 days of repeated treatment, as well as whether the effectiveness of lorcaserin is surmounted when larger unit doses of cocaine are made available. Lorcaserin not only retained its effectiveness to decrease cocaine selfadministration across the entire 14-day treatment period, but it also continued to decrease cocaine self-administration even when larger unit doses of cocaine were available. A similar downward shift in the dose-response curve for cocaine self-administration has been reported for squirrel monkeys treated acutely with Ro 60-0175 (Manvich et al, 2012) . These findings are important because they suggest that individuals would not become tolerant to the effects of 
